Compare PepsiCo, Inc. (PEP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs TG Therapeutics Inc — how do they compare? PepsiCo, Inc. trades at $135.75 (market cap $184.26B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: PepsiCo, Inc. is far larger — about 22.3× TG Therapeutics Inc's market cap, and PepsiCo, Inc. pays a 4.39% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PEP | TGTX | |
|---|---|---|
Market Cap | $184.26B | $8.26B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $59.06 |
52-Week Low | $134.98 | $26.39 |
Enterprise Value | $226.76B | $8.50B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.65, up 0.14% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts anticipate Q1 2026 results.
The outlook is mixed: strong profitability and dividend yield near 4% support value, but price sensitivity and debt levels pose risks. Analyst consensus is a $158.79 price target with a 'Hold' bias. Investors should weigh earnings consistency against margin pressures from recent pricing strategies.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
